BR112014011064A8 - 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives - Google Patents

2-oxo-oxazolidin-3,5-diyl antibiotic derivatives

Info

Publication number
BR112014011064A8
BR112014011064A8 BR112014011064A BR112014011064A BR112014011064A8 BR 112014011064 A8 BR112014011064 A8 BR 112014011064A8 BR 112014011064 A BR112014011064 A BR 112014011064A BR 112014011064 A BR112014011064 A BR 112014011064A BR 112014011064 A8 BR112014011064 A8 BR 112014011064A8
Authority
BR
Brazil
Prior art keywords
oxazolidin
oxo
diyl
antibiotic derivatives
alkyl
Prior art date
Application number
BR112014011064A
Other languages
Portuguese (pt)
Other versions
BR112014011064A2 (en
Inventor
Hubschwerlen Christian
Rueedi Georg
Surivet Jean-Philippe
Zumbrunn Acklin Cornelia
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112014011064A2 publication Critical patent/BR112014011064A2/en
Publication of BR112014011064A8 publication Critical patent/BR112014011064A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE ANTIBIÓTICOS 2-OXO-OXAZOLIDIN-3,5-DIILA. A invenção refere-se aos compostos anti-bacterianos da fórmula I em que R1a representa H ou carboxi e R1b representa H, ou R1a e R1b representam em conjunto seja o grupo *-C (O) -NH-S-# ou o grupo *-C (OH) =N-S-# em que "*" representa o ponto de ligação de R1a e "#" representa o ponto de ligação de R1b; R2 representa H, alquila(C1-C3), hidroxi-alquila(C1-C3), benzila ou cicloalquila(C3-C5); R3 representa H ou halogênio; U representa N ou CR4; em que R4 é H ou alcoxi(C1-C3); A representa CH, B representa NH e m representa 1 ou 2 e n representa 1 ou 2; ou A representa N, B está ausente, m representa 2 e n representa 2; Y representa CH ou N; e Q representa O ou S; e os sais de tais compostos.ANTIBIOTIC DERIVATIVES 2-OXO-OXAZOLIDIN-3,5-DIYLA. The invention relates to antibacterial compounds of the formula I in which R1a represents H or carboxy and R1b represents H, or R1a and R1b together represent either the group *-C(O)-NH-S-# or the group *-C(OH)=N-S-# where "*" represents the attachment point of R1a and "#" represents the attachment point of R1b; R2 represents H, (C1-C3)alkyl, hydroxy(C1-C3)alkyl, benzyl or (C3-C5)cycloalkyl; R3 represents H or halogen; U represents N or CR4; wherein R4 is H or (C1-C3)alkoxy; A represents CH, B represents NH and m represents 1 or 2 and n represents 1 or 2; or A represents N, B is absent, m represents 2 and n represents 2; Y represents CH or N; and Q represents O or S; and the salts of such compounds.

BR112014011064A 2011-11-08 2012-11-07 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives BR112014011064A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011054968 2011-11-08
PCT/IB2012/056236 WO2013068948A1 (en) 2011-11-08 2012-11-07 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives

Publications (2)

Publication Number Publication Date
BR112014011064A2 BR112014011064A2 (en) 2017-06-13
BR112014011064A8 true BR112014011064A8 (en) 2017-12-26

Family

ID=47258051

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011064A BR112014011064A8 (en) 2011-11-08 2012-11-07 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives

Country Status (20)

Country Link
US (1) US9079922B2 (en)
EP (1) EP2776431B1 (en)
JP (1) JP6030146B2 (en)
KR (1) KR20140096337A (en)
AR (1) AR088691A1 (en)
AU (1) AU2012335207B2 (en)
BR (1) BR112014011064A8 (en)
CA (1) CA2854264A1 (en)
CL (1) CL2014001154A1 (en)
ES (1) ES2581056T3 (en)
HK (1) HK1202288A1 (en)
IL (1) IL232463A0 (en)
IN (1) IN2014CN04126A (en)
MX (1) MX344529B (en)
PL (1) PL2776431T3 (en)
RU (1) RU2616609C2 (en)
SG (1) SG11201401710PA (en)
TW (1) TWI594996B (en)
WO (1) WO2013068948A1 (en)
ZA (1) ZA201404176B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003370A (en) 2008-10-07 2011-04-28 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds.
MA38588B1 (en) 2013-04-16 2018-04-30 Idorsia Pharmaceuticals Ltd Bi-aromatic antibacterial derivatives
AR096135A1 (en) 2013-05-02 2015-12-09 Actelion Pharmaceuticals Ltd DERIVATIVES OF QUINOLONA
AR102256A1 (en) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH REPLACEMENT OF AMINOALCOXI
MA41168A (en) 2014-12-17 2017-10-24 Acraf NEW ANTIBACTERIAL COMPOUNDS
MA41169A (en) * 2014-12-17 2017-10-24 Acraf WIDE-SPECTRUM ANTIBACTERIAL COMPOUNDS
BR112018016208A2 (en) * 2016-02-08 2018-12-18 Redx Pharma Plc heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their uses as antibacterial compounds
GB201602235D0 (en) * 2016-02-08 2016-03-23 Redx Pharma Plc Antibacterial compounds
WO2017137743A1 (en) * 2016-02-08 2017-08-17 Redx Pharma Plc Antibacterial compounds
AU2017276626A1 (en) 2016-06-08 2018-12-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. New antibacterial compounds
TW201833120A (en) 2017-02-17 2018-09-16 瑞士商愛杜西亞製藥有限公司 Aryloxazolidinone antibiotic compounds
JP7148991B2 (en) * 2017-06-08 2022-10-06 バグワークス・リサーチ・インコーポレイテッド Heterocyclic compound useful as an antibacterial agent and method for producing the same
ES2952989T3 (en) * 2017-11-29 2023-11-07 Bugworks Res Inc Antibacterial heterocyclic compounds and their synthesis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149104A (en) 1961-01-03 1964-09-15 Sterling Drug Inc 4-hydroxy-7-styryl-1, 8-naphthyridine-3-carboxylic acids and esters
CA1006521A (en) 1972-12-18 1977-03-08 Minoru Sugita Piperazine derivatives and process for preparing them
GB1598915A (en) 1977-09-20 1981-09-23 Bellon Labor Sa Roger 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them
SE444566B (en) 1977-09-20 1986-04-21 Bellon Labor Sa Roger 7-DIALKYLAMINE-6-HALOGEN-4-OXO-1,4-DIHYDROQINOLINE-3-CARBOXYLIC ACID, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION OF THEREOF
CS274601B2 (en) 1983-07-27 1991-09-15 Dainippon Pharmaceutical Co Method of 1,8-naphthyridine derivative production
JPS62205060A (en) 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd 8-substituted quinolonecarboxylic acid derivative
AU618235B2 (en) 1986-03-31 1991-12-19 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives, their preparation and use
JP2631854B2 (en) 1987-12-23 1997-07-16 藤本製薬株式会社 Novel 1,8-naphthyridine derivative
DE4301246A1 (en) 1993-01-19 1994-07-21 Bayer Ag Quinolone and naphthyridonecarboxylic acid derivatives
WO2004002973A1 (en) 2002-06-28 2004-01-08 Kaneka Corporation Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for the synthesis thereof and process for preparation of the intermediates
EP1620098B1 (en) * 2003-04-30 2008-06-11 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
CN1898238A (en) * 2003-12-18 2007-01-17 莫弗凯姆联合化学股份公司 Oxazolidinone-quinolone hybrid antibiotics
WO2006024741A2 (en) 2004-07-30 2006-03-09 Palumed S.A. Hybrid qa molecules wherein q is an aminoquinoline and a is an antibiotic residue, their synthesis and their uses as antibacterial agent
CA2578081A1 (en) 2004-09-01 2006-03-09 Ubitrak Inc. System for gaming chip identification and counting
US20090156577A1 (en) 2004-09-09 2009-06-18 Benjamin Davis 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd Antibacterial agents
CL2007003232A1 (en) * 2006-11-10 2008-06-27 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM 5-HYDROXIMETHYL OXAZOLIDIN-2-ONA; PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS; AND ITS USE TO TREAT AND PREVENT BACTERIAL INFECTIONS.
CL2008001002A1 (en) * 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
CL2008001003A1 (en) * 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
ES2380398T3 (en) * 2007-12-18 2012-05-11 Actelion Pharmaceuticals Ltd. 5-Aminocyclylmethyl-oxazolidin-2-one derivatives
EP2254887B9 (en) * 2008-02-22 2013-05-29 Actelion Pharmaceuticals Ltd. Oxazolidinone derivatives
MX2011003370A (en) 2008-10-07 2011-04-28 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds.
TWI436999B (en) * 2008-10-10 2014-05-11 Actelion Pharmaceuticals Ltd Oxazolidinyl antibiotics
WO2010041219A1 (en) * 2008-10-10 2010-04-15 Actelion Pharmaceuticals Ltd 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents
TW201121965A (en) 2009-09-28 2011-07-01 Lg Life Sciences Ltd Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis
CN101792443A (en) 2010-03-09 2010-08-04 北京欧凯纳斯科技有限公司 Fluoro-carbostyril derivative as well as preparation method and application thereof

Also Published As

Publication number Publication date
TW201326166A (en) 2013-07-01
TWI594996B (en) 2017-08-11
SG11201401710PA (en) 2014-09-26
JP6030146B2 (en) 2016-11-24
RU2014123109A (en) 2015-12-20
JP2014532754A (en) 2014-12-08
EP2776431B1 (en) 2016-05-04
CA2854264A1 (en) 2013-05-16
AU2012335207B2 (en) 2017-05-25
CL2014001154A1 (en) 2014-09-12
KR20140096337A (en) 2014-08-05
ZA201404176B (en) 2016-05-25
HK1202288A1 (en) 2015-09-25
AR088691A1 (en) 2014-06-25
IL232463A0 (en) 2014-06-30
AU2012335207A1 (en) 2014-07-03
RU2616609C2 (en) 2017-04-18
PL2776431T3 (en) 2016-11-30
BR112014011064A2 (en) 2017-06-13
MX344529B (en) 2016-12-19
CN103917539A (en) 2014-07-09
WO2013068948A1 (en) 2013-05-16
US9079922B2 (en) 2015-07-14
US20150051188A1 (en) 2015-02-19
MX2014005637A (en) 2014-06-23
ES2581056T3 (en) 2016-08-31
EP2776431A1 (en) 2014-09-17
IN2014CN04126A (en) 2015-07-10

Similar Documents

Publication Publication Date Title
BR112014011064A8 (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
CY1120066T1 (en) KINOLON UNION
CY1120477T1 (en) Receiver-actuator actuator actuated by sub-multipliers
CY1124537T1 (en) PYRIDONE DERIVATIVE HAVING A TETRAHYDROPYRANYL METHYL GROUP
EA201700230A1 (en) DETERMINED AMINOPYRIDINES, COMPOSITIONS ON THEIR BASIS AND METHODS OF THEIR APPLICATION
BRPI1009637A2 (en) compound, composition and use of a compound
PE20151781A1 (en) PYRIDONAMIDES AS SODIUM CHANNEL MODULATORS
CY1121677T1 (en) COMPOUNDS OF DIMETHYLOBENZOIC ACID
CY1117688T1 (en) Tetrahydropyrrolothiazine compounds
MX343596B (en) Nematocidal sulfonamides.
MX2011011485A (en) Nematocidal sulfonamides.
CY1118623T1 (en) TETRAHYDROPYROLTHIAZINE COMPOUNDS AS BACE Suspensions
BR112015016580A2 (en) nitrogen-containing heterocyclic compound or salt thereof
EA201691119A1 (en) DERIVATIVES OF UREA OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS
BR112015009777A2 (en) amine derivative or salt thereof
BR112015018509A2 (en) imidazo pyridine compounds
MA32956B1 (en) 5-AMINO-2- (1-HYDROXYETHYL) -TETRAHYDROPYRANE DERIVATIVES
ECSP11011318A (en) BENZOFURAN DERIVATIVES
BR112013018732A2 (en) new aryl benzocycloalkyl amide derivatives
BR112016026787A8 (en) QUINZAOLINE-4(3H)-ONE ANTIBACTERIAL DERIVATIVES
UA108760C2 (en) Calcium salts of the compound as anti-inflammatory, immunomodulatory and antiproliferative agents
CO6460726A2 (en) DERIVATIVE OF 5-HYDROXY-PYRIMIDIN-4-CARBOXAMIDE
MY160882A (en) Biocidal composition and method
CY1117026T1 (en) Heterocyclic compounds for the treatment or prevention of disorders caused by decreased serotonin neurotransmission, NERPIN.
MX2018002018A (en) Urea derivative and use therefor.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]